An analysis of potential costs of adverse events based on Drug Programs in Poland. Pulmonology focus

• Authors: Monika Szkultecka-Debek , Mariola Drozd , Karina Jahnz-Rozyk , Nina Kiepurska , Joanna Mazurek , Agnieszka Janowska , Piotr Paprzycki , Marta Adamczyk-Korbel , Beata Paluchowska , Kazimierz Drozd
• Languages of publication: EN

Abstracts

EN

The project was performed within the Polish Society for Pharmacoeconomics (PTFE). The objective was to estimate the potential costs of treatment of side effects, which theoretically may occur as a result of treatment of selected diseases. We analyzed the Drug Programs financed by National Health Fund in Poland in 2012 and for the first analysis we selected those Programs where the same medicinal products were used. We based the adverse events selection on the Summary of Product Characteristics of the chosen products. We extracted all the potential adverse events defined as frequent and very frequent, grouping them according to therapeutic areas. This paper is related to the results in the pulmonology area. The events described as very common had an incidence of ≥ 1/10, and the common ones ≥ 1/100, <1/10. In order to identify the resources used, we performed a survey with the engagement of clinical experts. On the basis of the collected data we allocated direct costs incurred by the public payer. We used the costs valid in December 2013. The paper presents the estimated costs of treatment of side effects related to the pulmonology disease area. Taking into account the costs incurred by the NHF and the patient separately e calculated the total spending and the percentage of each component cost in detail. The treatment of adverse drug reactions generates a significant cost incurred by both the public payer and the patient.

Keywords

EN

health care costs; adverse drug events; pulmonary medicine

• Publisher: De Gruyter Open
• Journal: Current Issues in Pharmacy and Medical Sciences
• Year: 2014
• Volume: 27
• Issue: 1
• Pages: 32-36

Dates

published

1 - 6 - 2014

received

17 - 3 - 2014

accepted

24 - 3 - 2014

online

30 - 5 - 2014

Contributors

author

Monika Szkultecka-Debek

• Department of Dermatology, Military Institute of Medicine, Warsaw, Poland

author

Mariola Drozd

• Department of Applied Pharmacy, Medical University of Lublin, Poland

author

Karina Jahnz-Rozyk

• Department of Immunology and Clinical Allergology, Military Institute of Medicine, Warsaw, Poland

author

Nina Kiepurska

• Department of Dermatology, Military Institute of Medicine, Warsaw, Poland

author

Joanna Mazurek

• Department of Immunology and Clinical Allergology, Military Institute of Medicine, Warsaw, Poland

author

Agnieszka Janowska

• Department of Functional Research, Institute of Rural Health in Lublin, Poland

author

Piotr Paprzycki

• Department of Functional Research, Institute of Rural Health in Lublin, Poland

author

Marta Adamczyk-Korbel

• Chair and Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Poland

author

Beata Paluchowska

• Department of Dermatology, Military Institute of Medicine, Warsaw, Poland

author

Kazimierz Drozd

• Department of Materials Engineering, Lublin University of Technology, Poland

References

• 1. Agencja Oceny Technologii Medycznych: Wytyczne oceny technologii medycznych (HTA) wersja 2.1. Warszawa, kwiecień 2009. Online: http://www.aotm.gov.pl/assets/files/wytyczne_hta/2009/Wytyczne_HTA_pl_MS_29052009.pdf, access: 2014.01.19
• 2. Allue N., Chiarello P., Bernal Delgado E., Castells X., Giraldo P., Martinez N., Sarsanedas E., Cots F.: Impacto economico de los eventos adversos en los hospitales espanoles a partir del Conjunto Minimo Basico de Datos” Assessing the economic impact of adverse events in Spanish hospitals by using administrative data. Gaceta Sanitaria, 2014, 1-2, s. 48-54.[Crossref]
• 3. Gautier S., Bachelet H., Bordet R., Caron J.: The cost of adverse drug reactions. Expert Opin. Pharmacother. 2003, 4, 3, s. 319-326.
• 4. Pattanaik S., Dhamija P., Malhotra S., Sharma N., Pandhi P.: Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northen India: a prospective study. British Journal of Clinical Pharmacology. 2009, 67, 3, s. 363-369.
• 5. Pliki parametryzujące. online: http://jgp.uhc.com.pl/doc/index.html, Access: 2014.01.06.
• 6. Rozporządzenie Ministra Zdrowia z 2 kwietnia 2012 roku w sprawie minimalnych wymagań jakie muszą spełniać analizy uwzględnione we wnioskach o objęcie refundacją i ustalenie urzędowej ceny zbytu oraz podwyższenie urzędowej ceny zbytu leku, środka spożywczego specjalnego przeznaczenia, wyrobu medycznego, ktore nie mają odpowiednika refundowanego w danym wskazaniu. Dz. U. 2012, poz. 388.
• 7. Szkultecka-Debek M., Drozd M., Wiśniewska N., Drozd K.: Adverse events (AE) cost assessed in Poland based on existing Drug programs - methodology of the project. Curr. Issues Pharm. Med. Sci. 2013, 26, 4, p. 422-424.
• 8. Ustawa z dn. 12 maja 2011 roku o refundacji lekow, środkow spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobow medycznych. Dz. U. 2011 nr 122 poz. 696 z poźn. zm.
• 9. Wiśniewska N., Szkultecka-Dębek M., Owczarek W., Paluchowska E., Jahnz-Rożyk K.: The direct costs of drug-induced skin reactions in Poland. Value in Health, 16, 7, 2013, s. A696.
• 10. Załącznik do Obwieszczenia Ministra Zdrowia z dnia 25 października 2013 r. w sprawie wykazu refundowanych lekow, środkow spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobow medycznych na dzień 1 listopada 2013 r. http://www2.mz.gov.pl/wwwmz/index?mr=q491&ms=383&ml=pl&mi=383&mx=0&mt=&my=419&ma=32785, access: 2013.11.04.

Identifiers

DOI

10.2478/cipms-2014-0009